Fluidigm Corp
F:FLB
Fluidigm Corp
Total Current Liabilities
Fluidigm Corp
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
F
|
Fluidigm Corp
F:FLB
|
Total Current Liabilities
$108.3m
|
CAGR 3-Years
36%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Current Liabilities
$15.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
14%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Current Liabilities
$6.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Waters Corp
NYSE:WAT
|
Total Current Liabilities
$1.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Current Liabilities
$2.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
9%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Current Liabilities
$8.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Fluidigm Corp
Glance View
Fluidigm Corp. is engaged in the development, manufacture, and marketing of biotechnology tools for life sciences research. The company is headquartered in South San Francisco, California and currently employs 615 full-time employees. The company went IPO on 2011-02-10. The firm operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. The company markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
See Also
What is Fluidigm Corp's Total Current Liabilities?
Total Current Liabilities
108.3m
USD
Based on the financial report for Dec 31, 2025, Fluidigm Corp's Total Current Liabilities amounts to 108.3m USD.
What is Fluidigm Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
14%
Over the last year, the Total Current Liabilities growth was 64%. The average annual Total Current Liabilities growth rates for Fluidigm Corp have been 36% over the past three years , 15% over the past five years , and 14% over the past ten years .
